Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Alumis Inc. Common StockNASDAQ: ALMS

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to -8557.2%

Net margin was -8557.2% in Q2 FY2026, down 10782.3 pp from a year earlier. On a trailing-twelve-month basis it was -5933.5%, down 4799.0 pp year over year.

What to watch

Whether net margin reaches the consensus estimate from 8 analysts of -38541.6% for the fiscal year ending Dec 2026, down from -1011.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-8557.2%-3212.4 pp QoQ
Last fiscal yearDec 2025
-1011.7%— YoY
LTMJun 2026
-5933.5%-4799.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10782.3 pp+202.6 pp+10984.9 pp
1 year—-37529.8 pp—
3 years—-17.6 pp—
5 years+1190.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1011.7%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ALMS compares with its peers on the latest reported figures

  • ALMS's LTM Jun 2026 net margin of -5933.5% is the 4th highest of the 6 companies compared; the peer median is -832.6%.
  • Its year-over-year change of -4799.0 pp is the 4th highest of 6, against a peer median of -100.2 pp.
ALMS Competitors Peer median
Net Margin for ALMS and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026121.5% +103.2 pp+173.4 pp
ANABAnaptysBio, Inc.LTM Mar 2026-11.5% +114.2 pp+1245.7 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
ALMSAlumis Inc. Common StockLTM Jun 2026-5933.5% -4799.0 pp—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-143627.1% -160183.1 pp-132411.6 pp
IFRXInflaRx N.V.LTM Mar 2026-146303.9% -111837.5 pp—
ODTXOdyssey Therapeutics, Inc.—— ——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
TLSATiziana Life Sciences LtdFY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding ALMS) -832.6%-100.2 pp-182.0 pp

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.